Grant awarded for Project ‘Development of Porous Gelatin Powder 73’

Regional policy touches all parts of the EU, and at all levels - from the EU-wide and national scale, to Europe's regions and local communities. It is part of the EU cohesion policy, the European Union's strategy to promote and support the overall harmonious development of its Member States and Regions. The policy is implemented by national and regional bodies in partnership with the European Commission.

Under this EU policy, EMCM has received a grant for the Project 'Development of Porous Gelatin Powder 73'.

Several years ago, EMCM developed a gel for the prevention of scar tissue and adhesions. This gel, Adcon, is used in spinal surgeries (i.e. hernia), and is a biocompatible gel providing a barrier and preventing adhesions.

The main raw material for Adcon is a gel foam, derived from pig gelatin, purchased from a US supplier. Notified Bodies are implementing increasingly rigid demands on materials from animal origin. As the current supplier does not provide information regarding the animal component of the porcine gelatin, CE certification is at risk and, therefore, Adcon can no longer be produced for the European market.

As a result, EMCM, in collaboration with FutureChemistry (a spin-off from the Radboud University, Nijmegen, The Netherlands) is developing a gel foam based on a patented technology by FutureChemistry: 'CONTINUOUS FLOW PRODUCTION OF GELATIN NANOPARTICLES’. This powder is referred to as PGP-73.

The importance of the successful development and market introduction not only benefits EMCM, but foremost patients, surgeons and health insurers. Adhesions tend to result in complications, revision surgeries, and pain for the patient. Also, there is an economic benefit; currently, the gel foam is purchased from a foreign supplier while in the new situation, the gel foam (PGP-73) will be produced in the region.


 

Top